We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.71%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$33.3B
AUM Growth
-$783M
(-2.3%)
Cap. Flow
-$715M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
15.9%
Holding
3,039
New
28
Increased
1,056
Reduced
1,268
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$29M |
| 2 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$14M |
| 3 |
Microsoft
MSFT
|
+$10.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$10.5M |
| 5 |
iShares Russell 1000 Growth ETF
IWF
|
+$6.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$34.4M |
| 2 |
FRX
FOREST LABORATORIES INC
FRX
|
+$32.2M |
| 3 |
ExxonMobil
XOM
|
+$23.9M |
| 4 |
Warner Bros
WBD
|
+$15.4M |
| 5 |
RTX Corp
RTX
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.81% |
| 2 | Financials | 14.8% |
| 3 | Healthcare | 13.73% |
| 4 | Industrials | 10.72% |
| 5 | Energy | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NCI
1701
DELISTED
Navigant Consulting, Inc.
NCI
| $1.1M | ﹤0.01% |
79,000
+750
| +1% | +$12.1K |
|
1702
Morningstar
MORN
$7.47B
| $1.09M | ﹤0.01% |
16,121
-100
| -0.6% | -$6.84K |
|
|
HRG
1703
DELISTED
HRG Group, Inc.
HRG
| $1.09M | ﹤0.01% |
83,391
+1,300
| +2% | +$16.3K |
|
|
AHT
1704
Ashford Hospitality Trust
AHT
$20.8M
| $1.09M | ﹤0.01% |
114
| – | – |
|
1705
Bloomin' Brands
BLMN
$774M
| $1.09M | ﹤0.01% |
59,224
-2,050
| -3% | -$37.6K |
|
|
ZNGA
1706
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $1.08M | ﹤0.01% |
401,356
+4,800
| +1% | +$14.4K |
|
|
BGC
1707
DELISTED
General Cable Corporation
BGC
| $1.08M | ﹤0.01% |
71,790
+440
| +0.6% | +$9.63K |
|
|
ACHN
1708
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.08M | ﹤0.01% |
108,417
+1,680
| +2% | +$15.6K |
|
1709
Celldex Therapeutics
CLDX
$2.99B
| $1.08M | ﹤0.01% |
5,561
-470
| -8% | -$102K |
|
1710
Vanguard Total Bond Market
BND
$158B
| $1.08M | ﹤0.01% |
13,135
-55,826
| -81% | -$4.58M |
|
|
RSTI
1711
DELISTED
Rofin-Sinar Technologies Inc
RSTI
| $1.08M | ﹤0.01% |
46,659
+200
| +0.4% | +$4.62K |
|
|
GLOG
1712
DELISTED
GASLOG LTD
GLOG
| $1.07M | ﹤0.01% |
48,836
-340
| -0.7% | -$8.76K |
|
1713
Globus Medical
GMED
$11B
| $1.07M | ﹤0.01% |
54,375
-4,670
| -8% | -$96.1K |
|
1714
WesBanco
WSBC
$4.01B
| $1.07M | ﹤0.01% |
34,976
-100
| -0.3% | -$3.06K |
|
|
VISN
1715
Vistance Networks Inc
VISN
$2.76B
| $1.07M | ﹤0.01% |
44,608
-343
| -0.8% | -$8.41K |
|
|
KKD
1716
DELISTED
KRISPY KREME DOUGHNUTS INC
KKD
| $1.07M | ﹤0.01% |
62,140
-150
| -0.2% | -$2.46K |
|
1717
ArcBest
ARCB
$3.19B
| $1.06M | ﹤0.01% |
28,542
-900
| -3% | -$34.1K |
|
1718
TriMas Corp
TRS
$1.46B
| $1.06M | ﹤0.01% |
54,771
-157
| -0.3% | -$4.07K |
|
|
SPWR
1719
DELISTED
SunPower Corporation Common Stock
SPWR
| $1.06M | ﹤0.01% |
47,885
+2,313
| +5% | +$56.4K |
|
|
SPNC
1720
DELISTED
Spectranetics Corp
SPNC
| $1.06M | ﹤0.01% |
39,951
-15
| -0% | -$403 |
|
1721
Innospec
IOSP
$2.12B
| $1.06M | ﹤0.01% |
29,520
+220
| +0.8% | +$8.93K |
|
1722
Mueller Water Products
MWA
$4.08B
| $1.06M | ﹤0.01% |
127,785
+640
| +0.5% | +$5.54K |
|
|
ZINC
1723
DELISTED
HORSEHEAD HLDG CORP COM STK (DE)
ZINC
| $1.06M | ﹤0.01% |
63,946
+100
| +0.2% | +$1.9K |
|
1724
AMN Healthcare
AMN
$1.25B
| $1.06M | ﹤0.01% |
67,258
+1,450
| +2% | +$20.7K |
|
|
FARO
1725
DELISTED
Faro Technologies
FARO
| $1.05M | ﹤0.01% |
20,787
+40
| +0.2% | +$2.08K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2014 Portfolio in Review
As of Q3 2014, RhumbLine Advisers held 3,039 positions worth $33.3B, down 2.3% from $34.1B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Trading was light in Q3 2014: portfolio turnover was 2.8%. RhumbLine Advisers opened 28 new positions and exited 57, leaving the 3,039-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2014 buy was Discovery, Inc. Series C Common Stock: 346,925 shares worth $12.9M.
- RhumbLine Advisers added most to Allergan plc in Q3 2014, an estimated $29M increase.
- RhumbLine Advisers's biggest Q3 2014 reduction was Apple, cutting an estimated $34.4M.
- RhumbLine Advisers fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $32.2M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $33.3B portfolio in Q3 2014.
- RhumbLine Advisers opened 28 new positions and closed 57 in Q3 2014.
- RhumbLine Advisers's portfolio value fell 2.3% quarter-over-quarter to $33.3B.
Based on RhumbLine Advisers's 13F filing for Q3 2014, filed 12 Nov 2014.